Imprecise information on significance of gene variants diminishes value of genetic panel testing
the ONA take:
Advances in technology provide people with the option of undergoing multigene testing, or panel testing, to determine their risk for developing various cancers.
However, an international consortium of authors caution clinicians about using these tests. Although the tests are helpful in identifying genetic mutations with the potential to increase a woman’s risk for breast and other cancers, clinicians need to be aware of, and share with patients, the limitations of test results.
Panel testing covers more than 100 genes, 21 of which are associated with breast cancer. Information about many genetic variants is lacking, and positive results may cause undue stress and anxiety over benign conditions.
In addition, patients may take significant or unnecessary risk-reducing interventions or screenings based on limited information.
The authors acknowledge that there is a significant body of evidence to support clinical action when some genetic variants are identified, such as BRCA1 and BRCA2 gene mutations; however, the implications of many other mutations are too imprecise and require further investigation.
They recommend that patients should be informed of the potential for uncertainty regarding the results.
Advances in technology provide people with the option of undergoing multigene testing determine their risk for developing cancer.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Aligning Patient Goals With End of Life Treatment Decisions
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|